Pramlintide

Educational overview

FDA-approved only as an adjunct to mealtime insulin; severe hypoglycemia is a boxed warning when used with insulin.

Pramlintide is a synthetic analogue of human amylin, the peptide hormone co-secreted with insulin from pancreatic beta cells. Human amylin readily forms insoluble fibrils, so three amino acids at positions 25, 28 and 29 were exchanged for proline residues taken from the rat sequence, producing a soluble molecule that retains receptor activity. Acting at amylin receptors in the area postrema and related hindbrain areas, it slows gastric emptying, suppresses inappropriate post-meal glucagon secretion and promotes satiation, complementing what injected insulin does. Its plasma half-life is short, on the order of 48 minutes, so the approved product is a mealtime subcutaneous injection rather than a long-acting one.

Amylin Pharmaceuticals ran the pivotal programme in insulin-treated diabetes. A 52-week randomised trial published in Diabetic Medicine in 2004 enrolled adults with type 1 diabetes and reported lower HbA1c and reduced body weight when pramlintide was added to insulin, compared with insulin alone, alongside more nausea and, during the early weeks, more severe hypoglycaemia. Companion trials in insulin-treated type 2 diabetes described a similar pattern of modest glycaemic benefit without the weight gain usually seen with insulin intensification. A separate phase 2 trial published in 2007 tested pramlintide in adults with obesity and without diabetes and reported progressive but modest weight loss; that indication was never carried to approval.

The FDA approved pramlintide as Symlin in March 2005 for adults with type 1 or type 2 diabetes on mealtime insulin who have not reached glucose targets despite insulin optimisation. The label carries a boxed warning for severe hypoglycaemia, which occurs mainly in type 1 diabetes and typically within three hours of an injection, and it states that pramlintide and insulin are drawn and injected separately rather than mixed in one syringe. The medicine was never authorised in the European Union. MedlinePlus records that pramlintide injection has since been discontinued in the United States, so the approval stands on paper while no product is commercially supplied.

Label storage instructions separate unopened from in-use product: unopened vials and pens are refrigerated and protected from light and from freezing, while an opened container is assigned a limited in-use period, refrigerated or at room temperature, and then discarded. Because the branded product has been discontinued in the United States, material encountered now is generally legacy stock, an import carrying another country's label, or a compounded preparation with a pharmacy beyond-use date. An inventory record that captures the source, presentation, strength, lot number, expiry and first-use date, with the route noted in a dose log, is what keeps such an entry interpretable afterwards.

Category

Amylin analogue

Routes represented

Subcutaneous (SubQ)

Approximate library half-life

0.8 hours; formulation-dependent and not dosing guidance

Storage context

Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.